Connection

Gregory Cote to Antineoplastic Combined Chemotherapy Protocols

Back to Details
This is a "connection" page, showing publications Gregory Cote has written about Antineoplastic Combined Chemotherapy Protocols.
Gregory Cote
Connection Strength
0.192
Antineoplastic Combined Chemotherapy Protocols
  1. NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo. Gynecol Oncol. 2015 Apr; 137(1):134-42.
    View in: PubMed
    Score: 0.093
  2. An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets. J Hematol Oncol. 2017 05 15; 10(1):107.
    View in: PubMed
    Score: 0.027
  3. Clinical outcomes for patients after surgery and radiation therapy for mesenchymal chondrosarcomas. J Surg Oncol. 2016 Dec; 114(8):982-986.
    View in: PubMed
    Score: 0.026
  4. A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells. BMC Cancer. 2014 Sep 19; 14:681.
    View in: PubMed
    Score: 0.023
  5. Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925. Br J Cancer. 2014 Jun 10; 110(12):2896-904.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.